Schedule of Notes Payable |
Schedule
of Notes Payable
|
|
March 31, |
|
|
December 31, |
|
|
|
2024 |
|
|
2023 |
|
On March 4, 2024, the Company
completed the sale of a promissory note to the Sanguine Group, LLC (“Sanguine”) in the principal amount of $360,000 for
a net purchase price of $300,000 after deduction of a $60,000 Original Issue Discount that is being amortized over the life of the
loan, pursuant to a securities purchase agreement between the Company and Sanguine. The Note matures on September 4, 2024, and bears
interest at a rate of 15% per annum, calculated based on a 360-day year. The Company also paid $15,000 of legal fees and a commitment
fee in the form of 2,500,000 shares of common stock, as noted, below. The proceeds were used to repay the Third AJB Note in the principal
amount of $300,000. The promissory note was repaid on April 22, 2024 out of proceeds received from debt financing received by SDT
Equities LLC. Pursuant to the Purchase Agreement, the Company paid a commitment fee to Sanguine in the form of 2,500,000
shares of the Company’s common stock (the “Commitment Fee Shares”). The Commitment Fee Shares resulted in a debt
discount of $73,454 that is being amortized over the life of the loan. |
|
$ |
360,000 |
|
|
$ |
- |
|
|
|
|
|
|
|
|
|
|
On August 18, 2023, the Company, through
its wholly-owned subsidiary, OWP Ventures, Inc., issued an unsecured promissory note of $35,000 to LDL8 Consulting, LLC for the purchase
of equipment from another vendor. The promissory note bears interest at 10% per annum and is due on demand. In the event of default,
the interest rate increases to 15% until repayment. |
|
|
35,000 |
|
|
|
35,000 |
|
|
|
|
|
|
|
|
|
|
On June 23, 2023,
the Company completed the sale of a Promissory Note in the principal amount of $300,000
(the “Third AJB Note”) to AJB Capital Investments LLC (“AJB Capital”) for an aggregate purchase price of
$276,000,
pursuant to a Securities Purchase Agreement between the Company and AJB Capital (the “Purchase Agreement”). The Company
received net proceeds of $262,500
after deduction of an original issue discount of $24,000,
$7,500
of legal fees and a $6,000
of broker fee, which were amortized as a debt discount over the life of the loan.
The Third AJB Note matured on March
23, 2024 (the “Maturity Date”), carried interest at a rate of 12%
per annum, and, following an event of default only, was convertible into shares of the Company’s common stock at a conversion
price equal to the lesser of the Volume Weighted Average Price (“VWAP”) during (i) the 10-trading
day period preceding the issuance date of the note, or (ii) the 10-trading day period preceding date of conversion of the Note. The
Note was also subject to covenants, events of defaults, penalties, default interest and other terms and conditions customary in
transactions of this nature.
Pursuant to the Purchase Agreement, the Company paid a commitment fee to AJB Capital in
the amount of $100,000
(the “Commitment Fee”) in the form of 1,666,667
shares of the Company’s common stock (the “Commitment Fee Shares”). During the period commencing on the six-month
anniversary of the closing date and ending on the five-year anniversary of the closing date, AJB Capital is entitled to be issued
additional shares of common stock or receive a cash payment to the extent AJB Capital’s sale of the Commitment Fee Shares has
resulted in net proceeds in an amount less than the Commitment Fee. The Commitment Fee Shares resulted in a debt discount of $42,175
that was amortized over the life of the loan.
In connection with the issuance of the Third AJB Note and Commitment
Fee Shares, the Company entered into a Registration Rights Agreement with AJB Capital in which the Company agreed to file a
registration statement with the SEC within 180 days of June 23, 2023, registering the shares of common stock issuable under the
Third AJB Note and Purchase Agreement. The note was repaid on March 14, 2024 out of the proceeds received from the Sanguine Group
Note.
|
|
|
- |
|
|
|
300,000 |
|
|
|
|
|
|
|
|
|
|
Total notes payable |
|
|
395,000 |
|
|
|
335,000 |
|
Less:
unamortized debt discounts |
|
|
126,670 |
|
|
|
24,136 |
|
Notes payable, net of discounts |
|
|
268,330 |
|
|
|
310,864 |
|
Less:
current maturities |
|
|
268,330 |
|
|
|
310,864 |
|
Notes payable, long-term
portion |
|
$ |
- |
|
|
$ |
- |
|
|
Schedule of Notes Payable Debt Discounts |
The
Company recognized aggregate debt discounts on the notes payable to for the three months ended March 31, 2024, as follows:
Schedule
of Notes Payable Debt Discounts
|
|
March 31, |
|
|
December 31, |
|
|
|
2024 |
|
|
2023 |
|
|
|
|
|
|
|
|
Fair value of commitment shares
of common stock |
|
$ |
73,454 |
|
|
$ |
42,175 |
|
Original issue discounts |
|
|
60,000 |
|
|
|
24,000 |
|
Legal and brokerage fees |
|
|
15,000 |
|
|
|
13,500 |
|
Total debt discounts |
|
|
148,454 |
|
|
|
79,675 |
|
Amortization of debt discounts |
|
|
21,784 |
|
|
|
26,233 |
|
Unamortized debt discounts |
|
$ |
126,670 |
|
|
$ |
53,442 |
|
|
Schedule of Interest Expenses |
The
Company recognized interest expense for the three months ended March 31, 2024 and 2023, as follows:
Schedule
of Interest Expenses
|
|
March 31, |
|
|
March 31, |
|
|
|
2024 |
|
|
2023 |
|
|
|
|
|
|
|
|
Interest on convertible notes,
related party |
|
$ |
15,123 |
|
|
$ |
14,795 |
|
Interest on notes payable, related parties |
|
|
29,576 |
|
|
|
5,467 |
|
Interest on notes payable |
|
|
11,250 |
|
|
|
37,808 |
|
Amortization of debt discounts, related
parties |
|
|
110 |
|
|
|
- |
|
Amortization of debt discounts, common stock |
|
|
23,555 |
|
|
|
- |
|
Amortization of debt discounts |
|
|
22,365 |
|
|
|
- |
|
Total interest expense |
|
$ |
101,979 |
|
|
$ |
58,070 |
|
|